Institute for Stem Cell & Regenerative Medicine

at the University of Washington

Quellos High Throughput Screening Core

Timothy J Martins, Ph.D.
Director, Principal Scientist, Quellos High Throughput Screening Core

Dr. Timothy J Martins was one of the original scientists at ICOS Corporation and remained there for its entire 17 years of operation. An acquisition ended ICOS’ independent status and resulted in it becoming a wholly owned subsidiary of Eli Lilly & Co. Prior to that he received his BS in Biochemistry at UC Riverside, Ph.D. in Pharmacology at Univ. Washington School of Medicine and performed his postdoctoral fellowship at Harvard University's Biological Laboratories. Dr. Martins' department performed all high throughput screening assays for ICOS and was the primary provider of target-based, primary cell-based and pharmaceutical profiling data to project leaders and medicinal chemists involved in chemical optimization programs at the company. Besides providing high throughput screening and chemical optimization program support, his department oversaw ICOS' chemical repository that included library acquisition, storage, inventory and distribution functions. Prior to becoming their Director of Biomolecular Sciences and Technology, Dr. Martins served as an Associate Director, Research and was instrumental in ICOS' Bench to "First-in-Man" approach to research where he was directly involved in their PDE5 inhibitor (Cialis) and PDE4 inhibitor (clinical entry) discovery/optimization programs. Recently emerging from an early retirement, he is currently overseeing implementation of small molecule screening at the Core facility and general management of the screening laboratory.

James Annis, B.A., AAS
Research Scientist, Quellos High Throughput Screening Core

Mr. James Annis entered the biotech community in 1996 at Icogen Inc. where he worked with a team to pilot and characterize protein therapeutics for the treatment of disabling haplo-insufficiencies. This work has lead to IND's, clinical trials, worldwide patents, and market ready therapeutics. Joining Rosetta / Merck & Co., Inc. in 2004 he became involved in the development and industrialization of Lentiviral mediated shRNA HTS screening capabilities within the Molecular Profiling franchise. Additionally Mr. Annis has developed several HTS siRNA assays across multiple disease areas that were utilized for biological network validation, compound enhancement/suppression and target discovery. Mr. Annis holds a BA in Natural Sciences/Mathematics from Thomas Edison State College and an AAS in Biotechnology from SCCC.